Back to basics: do we need more immuno-oncology in the core curriculum?
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
Nina Bhardwaj receives the ESMO Immuno-Oncology Award 2022
According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines
Is there still a future for cancer vaccines?
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner
Is combining radiotherapy and immunotherapy a viable treatment option?
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
Benefits of immunotherapy in hepatocellular carcinoma are confirmed in Asian subpopulations
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
Nivolumab plus chemotherapy does not improve PFS in EGFR-mutated NSCLC
CheckMate 722 trial fails to meet its primary endpoint in patients with cancer progressing on one or two prior lines of EGFR tyrosine-kinase inhibitors
Serplulimab plus chemotherapy prolongs progression-free survival in PD-L1-positive oesophageal squamous cell carcinoma
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
Test for gut microbiota predicts survival in patients receiving an immune checkpoint inhibitor
An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions
Dynamic immunoediting of tumours may hold the clue to effective treatment with immunotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Can new routes of administration have a place in the application of immunotherapy?
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients